Manages OA. 1.2 Rheumatoid Arthritis (RA). ANDA 206827, held by Aurobindo Pharma. Celecoxib.
As of Nov 15, 2026, ANDA 206827 (Celecoxib), held by Aurobindo Pharma, was first approved by FDA on Feb 1, 2016, with 5 approved supplements and 0 published complete response letters.
Celecoxib capsules are indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2016 | Original application | Approved |
| Dec 19, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 5, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 14, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 1, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters